Skip to main content

Zusammenfassung

Die Einteilung der Non-Hodgkin-Lymphome erfolgt durch die R.E.A.L.-Klassifikation nicht nur nach zellulärer Herkunft, Zytologie und Immunhistochemie, sie wurde durch zusätzliche zytogenetische Kriterien und auch durch die Einbeziehung der Lokalisation und von klinischen Eigenschaften aktualisiert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters, Falini B, Gatter KC, Grogan TM, Isaacson P, Knowles DM, Mason DY, Müller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA (1994) A Revised European American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group. Blood 84: 1361–1392

    PubMed  CAS  Google Scholar 

  2. Binet JL, Auquier A, Dighiero G et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198–206

    Article  PubMed  CAS  Google Scholar 

  3. Rai KR, Sawitzky A, Cronkite EP, Chanana AD, Levy RM, Pasternak BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234

    PubMed  CAS  Google Scholar 

  4. Unterhalt M, Hermann R, Tiemann M, Pawaresch R, Steinjrumper L, Nahler M, Reuss-Borst M, Tirier C, Neubauer A, Freund M, Kreuser ED, Dietzfelbinger H, Bodenstein H, Engert A, Stauder R, Eimermacher H, Landys K, Hiddemann W (1996) Prednimustine, mitoxantrone (PmN9 vs. cyclophosphamide, vincristine, Prednisone (COP) for the treatment of advanced lowgrade non-Hodgkin’s lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 10: 836–843

    PubMed  CAS  Google Scholar 

  5. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842–854

    Article  PubMed  CAS  Google Scholar 

  6. Shipp MA et al. (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–949

    Article  Google Scholar 

  7. Attal M, Harrousseau JL, Stoppa AM et al. (1996) A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91–97

    Article  PubMed  CAS  Google Scholar 

  8. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage Chemotherapie in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333: 1540–1545

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weissinger, F., Kreipe, H.H., Wilhelm, M. (2000). Non-Hodgkin-Lymphome. In: König, B., Reinhardt, D., Schuster, HP. (eds) Kompendium der praktischen Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59754-1_76

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59754-1_76

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64110-7

  • Online ISBN: 978-3-642-59754-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics